As you noted in your quote of my comments, I said that CYDY got overseas approval to an extent. I was referring to Compassionate Special Permits (CSPs) authorized by the Philippine FDA, to be more specific.
And I noted previously that CYDY, "...revealed that Chiral Pharma Corporation placed its first purchase order for leronlimab under a compassionate special permit (CSP), to treat critically ill coronavirus (COVID-19) patients in the Philippines."
So please don't tell me that I'm being ludicrous in comparing that to Humanigen's rolling submission to the UK's MHRA. I made no such comparison.
I don't have 100% trust in any of our government agencies or NGO's, including NASDAQ, the SEC, or the FDA. I think it makes sense for the CEO's of small, independent biotechs to have a Plan B for product launch in this regulatory environment, including seeking approval overseas, in order to generate revenue, and, in CYDY's case, to provide a product that can be used to save Covid patients who are on mechanical ventilation, which I value highly.
We on this board seem to collectively be more optimistic than the market is generally about our pending FDA approval, despite that approval having record-breaking sales potential, and despite the fact that that huge revenue windfall could be directed to the small, obscure entity that we are. A purse that large being awarded to a small, independent biotech defies common practice. People are betting against us because they think it is safe to do so. This will be a paradigm shift.
Market Data 
Markets 
